Results Of ADAGIO Study With AZILECT(R) In Parkinson's Disease Published In New England Journal Of Medicine

Results from the ADAGIO trial, published online today in The New England Journal of Medicine, demonstrated that Parkinson's disease patients receiving AZILECT® (rasagiline) 1mg/day at the start of the study (early-start group) experienced superior benefit over 18 months compared with those who started the exact same treatment nine months later (delayed-start group).